DOCSLIB.ORG

To USP 39–NF 34, First Supplement the Following Index Is For

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Index to USP 39–NF 34, First Supplement The following Index is for convenience and informational use only and shall not be used for interpretive purposes. In addition to official articles, this Index may also include items recently omitted from the USP–NF in the indicated Book or Supplement. The requirements stated in the General Notices and Requirements section of the USP–NF apply to all articles recognized in the USP–NF and to all general chapters unless specifically stated otherwise. Although this revision (USP 39–NF 34 1S) is generally official beginning August 1, 2016; particular provisions may indicate another earlier or later official date. In addition, the monographs and general chapters listed in this Index may reference other general chapter specifications. The articles listed in this Index are not intended to be autonomous standards and should only be interpreted in the context of the entire USP–NF publication. For the most current version of the USP–NF please see the USP–NF Online Combined Index to USP 39 and NF 34 Abaca-Acety I-1 Combined Index to USP 39 and NF 34, including First Supplement Page citations refer to the pages of Volumes 1, 2, 3, and 4 of USP 39±NF 34 and its First Supplement. This index is repeated in its entirety in each volume. 1±2280 Volume 1 2281±4454 Volume 2 4455±6446 Volume 3 6447±7608 Volume 4 7609±8194 First Supplement Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. and (salts of) chlorpheniramine, and tramadol hydrochloride oral A dextromethorphan, and suspension, 6214 pseudoephedrine, oral powder and tramadol hydrochloride tablets, 2323 Abacavir containing at least three of the Acetanilide, 2084 oral solution, 2281 following, 2306 Acetate sulfate, 2283 and (salts of) chlorpheniramine, methyl, 2126 tablets, 2282 dextromethorphan, and Acetate buffer, 2166 and lamivudine tablets, 7977 pseudoephedrine, oral solution TS, 2167 Abiraterone containing at least three of the Acetazolamide, 2325, 7980 acetate, 2285 following, 2308 for injection, 2325, 7981 acetate tablets, 2286 and (salts of) chlorpheniramine, oral suspension, 2326 Absolute dextromethorphan, and tablets, 2327, 7982 alcohol, 2085 pseudoephedrine, tablets containing at Acetic acid, 2084, 7139 ether, 2084 least three of the following, 2310 ammonium acetate buffer TS, 2167 Absorbable chlorpheniramine maleate, and diluted, 2084, 7139 dusting powder, 3640 dextromethorphan hydrobromide double-normal (2 N), 2177 gelatin film, 4096 tablets, 2312 glacial, 2084, 2327 gelatin sponge, 4096 and codeine phosphate capsules, 2314 glacial, TS, 2167 surgical suture, 5978 and codeine phosphate oral solution, 2315 and hydrocortisone otic solution, 4223 Absorbent and codeine phosphate oral suspension, irrigation, 2328 cotton, 2084 2316 metaphosphoric, TS, 2172 gauze, 4094 and codeine phosphate tablets, 2317 otic solution, 2328 odorless paper, 2131 dextromethorphan hydrobromide, strong, TS, 2167 Acacia, 7137 doxylamine succinate, and Acetic acid in peptides, 357 syrup, 7137 pseudoephedrine hydrochloride oral Acetic anhydride, 2084 Acarbose, 2288 solution, 2318 Acetohexamide, 2329 Acebutolol hydrochloride, 2289 and diphenhydramine citrate tablets, 2319 tablets, 2329 capsules, 2291 diphenhydramine hydrochloride, and Acetohydroxamic acid, 2329 Acepromazine maleate, 2292 pseudoephedrine hydrochloride tablets, tablets, 2330 injection, 2293 2320 Acetone, 2084, 7140 tablets, 2293 and hydrocodone bitartrate tablets, 4214 anhydrous, 2084 Acesulfame potassium, 7138 isometheptene mucate, and neutralized, 2084, 2167 Acetal, 2084 dichloralphenazone capsules, 4407 Acetonitrile, 2084 Acetaldehyde, 2084 and oxycodone capsules, 5225 spectrophotometric, 2084 TS, 2167 and oxycodone tablets, 5227 Acetophenone, 2084 Acetaminophen, 2294 and pentazocine tablets, 5326 p-Acetotoluidide, 2084 aspirin and caffeine tablets, 2302 and propoxyphene hydrochloride tablets, Acetylacetone, 2084 and aspirin tablets, 2301 5582 Acetyl chloride, 2084 butalbital and caffeine capsules, 2827 and propoxyphene napsylate tablets, 5587 Acetylcholine chloride, 2084, 2331 butalbital and caffeine tablets, 2828 and pseudoephedrine hydrochloride for ophthalmic solution, 2332 and caffeine tablets, 2303, 7979 tablets, 2322 Acetylcysteine, 2333 capsules, 2296 oral solution, 2296 and isoproterenol hydrochloride inhalation and (salts of) chlorpheniramine, for effervescent oral solution, 2297 solution, 2334 dextromethorphan, and suppositories, 2298 solution, 2334 pseudoephedrine, capsules containing at oral suspension, 2298 N-Acetylglucosamine, 6447 least three of the following, 2304 tablets, 2299 3-Acetylthio-2-methylpropanoic acid, 2085 extended-release tablets, 2300 Acetyltributyl citrate, 7141 I-2 Acety-Alumi Combined Index to USP 39 and NF 34 Acetyltriethyl citrate, 7141 Isoproterenol sulfate inhalation, 4420 Alfuzosin hydrochloride, 2371 N-Acetyltyrosine, 6448 Lidocaine topical, 4560 extended-release tablets, 2372 N-Acetyl-L-tyrosine ethyl ester, 2085 Metaproterenol sulfate inhalation, 4757 Alginates assay 〈311〉, 288 Acid Polymyxin B sulfate and bacitracin zinc Alginic acid, 7148 acrylic, 2085 topical, 5446 Alizarin complexone, 2086 alpha lipoic, 6731 Povidone±iodine topical, 5483 Alkaline dehydroacetic, 7272 Terbutaline sulfate inhalation, 6055 borate buffer, 2166 ferric chloride TS, 2167 Thimerosal topical, 6116 cupric citrate TS, 2167 ferrous sulfate TS, 2167 Tolnaftate topical, 6194 cupric citrate TS 2, 2167 iminodiacetic, 2121 Triamcinolone acetonide topical, 6237 cupric iodide TS, 2167 phthalate buffer, 2165 cupric tartrate TS, 2167 stannous chloride TS, 2167 mercuric-potassium iodide TS, 2167 stannous chloride TS, stronger, 2167 phosphatase enzyme, 2086 Acid-neutralizing capacity 〈301〉, 287 Agar, 2085, 7143 picrate TS, 2167 Acidulated phosphate and sodium fluoride Agarose, 2085 pyrogallol TS, 2174 topical solution, 5874 Air, medical, 2348 sodium hydrosulfite TS, 2167 Acitretin, 2335 Air-helium certified standard, 2085 Alkyl (C12-15) benzoate, 7149 capsules, 2336 Alanine, 2349 Alkylphenoxypolyethoxyethanol, 2086 Acoustic emission 〈1005〉, 763 L-Alanyl-L-glutamine, 6450 Allantoin, 2377 Acrylic acid, 2085 Albendazole, 2350 Allopurinol, 2378 Activated oral suspension, 2351 oral suspension, 2380 alumina, 2085 tablets, 2351 tablets, 2380 charcoal, 2085, 3080 Albumen TS, 2167 Allyl isothiocyanate, 2381 magnesium silicate, 2085 Albumin Almond oil, 7149 Acyclovir, 2338 bovine serum, 2085 Almotriptan capsules, 2339 human, 2352 tablets, 2384 for injection, 2340 rAlbumin human, 7144 Almotriptan malate, 2381 ointment, 2341 Albuterol, 2353 Aloe, 2385 oral suspension, 2342 sulfate, 2357 Alpha tablets, 2342 tablets, 2353 lipoic acid, 6731 Adamantane, 2085 extended-release tablets, 2354 Alpha-chymotrypsin, 2086 Adapalene, 2343 Alclometasone dipropionate, 2358 Alpha cyclodextrin hydrate, 2086 gel, 7983 cream, 2359 Alpha-(2-(methylamino)ethyl)benzyl alcohol, Ademetionine disulfate tosylate, 6449 ointment, 2360 2086 Adenine, 2346 Alcohol, 2085, 2361 Alphanaphthol, 2086 sulfate, 2085 70 percent, 80 percent, and 90 percent, Alphazurine 2G, 2162 Adenosine, 2347 2085 Alprazolam, 2386 injection, 2348 absolute, 2085 oral suspension, 2387 Adipic acid, 2085, 7142 aldehyde-free, 2085 tablets, 2388 Admissions alpha-(2-(methylamino)ethyl)benzyl, 2086 extended-release tablets, 2389, 7986 to NF 34, 7125 amyl, 2085 orally disintegrating tablets, 2393 to USP 39, xxxv tert-amyl, 2089 Alprenolol hydrochloride, 2086 Adulteration of dietary supplements with butyl, 7186 Alprostadil, 2395 drugs and drug analogs 〈2251〉, 7821 dehydrated, 2085, 2363 injection, 2397 Advisory Groups, xx, 7621 dehydrated isopropyl, 2085 Alteplase, 2398 denaturated, 2085 for injection, 2401 denaturated, TS, 2170 Alternative microbiological sampling methods determination 〈611〉, 454 for nonsterile inhaled and nasal products in dextrose injection, 2365 〈610〉, 452 Aerosol diluted, 2086, 7146 Altretamine, 2403 Fluticasone propionate and salmeterol, injection, dehydrated, 2364 capsules, 2404 inhalation, 4015 isobutyl, 2086 Alum, 2086 Aerosol isopropyl, 2086 ammonium, 2086, 2405 Bacitracin and polymyxin B sulfate topical, methyl, 2086 potassium, 2137, 2405 2673 neutralized, 2086 Alumina, 2086 Benzocaine, butamben, and tetracaine phenol TS, 2167 activated, 2086 hydrochloride topical, 2713 n-propyl, 2086 anhydrous, 2086 Benzocaine and menthol topical, 2716 rubbing, 2366 aspirin, codeine phosphate, and magnesia Benzocaine topical, 2704 secondary butyl, 2086 tablets, 2616 Betamethasone dipropionate topical, 2740 tertiary butyl, 2086 aspirin, and magnesia tablets, 2610 Dexamethasone sodium phosphate Alcoholic aspirin, and magnesium oxide tablets, inhalation, 3407 ammonia TS, 2167 2611 Dexamethasone topical, 3398 mercuric bromide TS, 2167 magnesia, and calcium carbonate Epinephrine bitartrate inhalation, 3715 potassium hydroxide TS, 2167 chewable tablets, 2409 Epinephrine inhalation, 3712 potassium hydroxide TS 2, 2174 magnesia, calcium carbonate, and Ergotamine tartrate inhalation, 3736 TS, 2167 simethicone chewable tablets, 2410 Fluticasone propionate inhalation, 4001 Alcoholometric table, 2274 magnesia, and calcium carbonate oral Inhalation and nasal drug products: Aldehyde dehydrogenase, 2086 suspension, 2408 aerosols, sprays, and powdersÐ Alendronate sodium, 2367, 7984 magnesia, and simethicone oral performance quality tests 〈601〉, 423 tablets, 2368 suspension, 2412 Isoetharine mesylate inhalation, 4401 Alfadex, 7147 magnesia, and simethicone chewable Isoproterenol hydrochloride inhalation, Alfentanil tablets,
Recommended publications
  • Wo 2009/081169 A2

    Wo 2009/081169 A2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 2 July 2009 (02.07.2009) WO 2009/081169 A2 (51) International Patent Classification: KJELLSON, Fred [SE/SE]; IoPharma Technologies AB, A61K 49/04 (2006.01) Ideon Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE). KLAVENESS, J o [NO/SE]; IoPharma Technologies (21) International Application Number: AB, Ideon Science Park, Ole Romers Vag 12, SE-223 70 PCT/GB2008/004268 Lund (SE). (22) International Filing Date: (74) Agent: KIDD, Sara; Frank B. Dehn 6 Co., St. Bride's 22 December 2008 (22.12.2008) House, 10 Salisbury Square, London EC4Y 8ID (GB). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, (30) Priority Data: EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, 0725070.7 21 December 2007 (21.12.2007) GB IL, IN, IS, IP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, (71) Applicant (for all designated States except US): IO- LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, PHARMA TECHNOLOGIES AB [SE/SE]; Ideon MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, Science Park, Ole Romers Vag 12, SE-223 70 Lund (SE).
  • Betamethasone Valerate Foam: a Look at the Clinical Data

    Betamethasone Valerate Foam: a Look at the Clinical Data

    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
  • Constipation: a Parent's Guide

    Constipation: a Parent's Guide

    CONSTIPATION: A PARENT’S GUIDE Twenty Questions About Constipation: Answers to Guide Parents and Professionals Constipation is the abnormally delayed or infrequent passage of hard stools. Most children, and many adults, too, become constipated from time to time. Often, the duration is short; occasionally it persists for months, even years. Although constipation can be uncomfortable, may create worry, and sometimes seem serious, fortunately it does not have long-term, troubling effects in most healthy children. This Booklet is designed to help you deal with childhood constipation by answering several questions and outlining management instructions for you to follow. Questions answered are: 1. What are the normal 11. What can we learn from patterns of bowel physical exam results? movements at 12. What is our treatment different ages? program for constipation? 2. What makes up bowel 13. How is the colon movements and how do cleaned out? they travel? 14. How are stools softened? 3. What is constipation? 15. Why is trying to have 4. When is constipation most bowel movements twice likely to occur? a day so important? 5. Why does constipation 16. What are the expected persist in some children? results of the treatment 6. Why would a child hold program? back stool and what 17. What do we do if the happens then? cleansing regimen is 7. How can proper toilet not successful? training help? 18. What is the long-term 8. Why would stool back up program for children in the colon? prone to constipation? 9. Why do some children 19. Does a special diet help have soiling accidents? resolve constipation? 10.
  • Albany-Molecular-Research-Regulatory

    Albany-Molecular-Research-Regulatory

    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
  • Clomifene Citrate(BANM, Rinnm) ⊗

    Clomifene Citrate(BANM, Rinnm) ⊗

    2086 Sex Hormones and their Modulators Profasi; UK: Choragon; Ovitrelle; Pregnyl; USA: Chorex†; Choron; Gonic; who received the drug for a shorter period.6 No association be- 8. Werler MM, et al. Ovulation induction and risk of neural tube Novarel; Ovidrel; Pregnyl; Profasi; Venez.: Ovidrel; Pregnyl; Profasi†. tween gonadotrophin therapy and ovarian cancer was noted in defects. Lancet 1994; 344: 445–6. Multi-ingredient: Ger.: NeyNormin N (Revitorgan-Dilutionen N Nr this study. The conclusions of this study were only tentative, 9. Greenland S, Ackerman DL. Clomiphene citrate and neural tube 65)†; Mex.: Gonakor. defects: a pooled analysis of controlled epidemiologic studies since the numbers who developed ovarian cancer were small; it and recommendations for future studies. Fertil Steril 1995; 64: has been pointed out that a successfully achieved pregnancy may 936–41. reduce the risk of some other cancers, and that the risks and ben- 10. Whiteman D, et al. Reproductive factors, subfertility, and risk efits of the procedure are not easy to balance.7 A review8 of epi- of neural tube defects: a case-control study based on the Oxford Clomifene Citrate (BANM, rINNM) ⊗ Record Linkage Study Register. Am J Epidemiol 2000; 152: demiological and cohort studies concluded that clomifene was 823–8. Chloramiphene Citrate; Citrato de clomifeno; Clomifène, citrate not associated with any increase in the risk of ovarian cancer 11. Sørensen HT, et al. Use of clomifene during early pregnancy de; Clomifeni citras; Clomiphene Citrate (USAN); Klomifeenisi- when used for less than 12 cycles, but noted conflicting results, and risk of hypospadias: population based case-control study.
  • Information for the User ZYTIGA 500 Mg Film-Coated Tablets Abiraterone

    Information for the User ZYTIGA 500 Mg Film-Coated Tablets Abiraterone

    Package leaflet: Information for the user ZYTIGA 500 mg film-coated tablets abiraterone acetate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What ZYTIGA is and what it is used for 2. What you need to know before you take ZYTIGA 3. How to take ZYTIGA 4. Possible side effects 5. How to store ZYTIGA 6. Contents of the pack and other information 1. What ZYTIGA is and what it is used for ZYTIGA contains a medicine called abiraterone acetate. It is used to treat prostate cancer in adult men that has spread to other parts of the body. ZYTIGA stops your body from making testosterone; this can slow the growth of prostate cancer. When ZYTIGA is prescribed for the early stage of disease where it is still responding to hormone therapy, it is used with a treatment that lowers testosterone (androgen deprivation therapy ). When you take this medicine your doctor will also prescribe another medicine called prednisone or prednisolone. This is to lower your chances of getting high blood pressure, having too much water in your body (fluid retention), or having reduced levels of a chemical known as potassium in your blood.
  • Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study

    Efficacy and Tolerability of Quinacrine Monotherapy and Albendazole Plus Chloroquine Combination Therapy in Nitroimidazole-Refractory Giardiasis: a Tropnet Study

    Klinik für Infektiologie & Spitalhygiene Efficacy and tolerability of quinacrine monotherapy and albendazole plus chloroquine combination therapy in nitroimidazole-refractory giardiasis: a TropNet study Andreas Neumayr, Mirjam Schunk, Caroline Theunissen, Marjan Van Esbroeck, Matthieu Mechain, Manuel Jesús Soriano Pérez, Kristine Mørch, Peter Sothmann, Esther Künzli, Camilla Rothe, Emmanuel Bottieau Journal Club 01.03.21 Andreas Neumayr Background on giardia treatment: • 1st-line treatment: 5-nitroimidazoles: metronidazole (1957), tinidazole, ornidazole, secnidazole • cure rate of 5NIs in 1st-line treatment: ~90% • in the last decade, an increase of 5NI-refractory giardia cases has been observed in travel medicine clinics across Europe: Hospital for Tropical Diseases, London: 2008: 15% --> 2013: 40% 70% of 5NI-refractory cases imported from India • 2nd-line treatment: effectiveness of a 2nd round with a 5NI: ~17% alternative drugs: albendazole, mebendazole, nitazoxanide, quinacrine, furazolidone, chloroquine, paromomycin 2012 TropNet member survey: 53 centres use 39 different treatment regimens, consisting of 7 different drugs in mono- or combination-therapy in various dosages and durations JC 01.03.21 Nabarro LE et al. Clin Microbiol Infect. 2015;21:791-6. • by 2013, there were only 13 reports of 2nd-line therapy for giardiasis (8 case series, 5 individual case reports): n=110 Cure rates Albendazole 6/32 18.7% Paromomycin 5/17 29.4% Nitazoxanide 2/5 40.0% Albendazole + 5-NI 42/53 79.2% Quinacrine 19/21 90.5% Quinacrine + 5-NI 14/14 100% Quinacrine + Paromomycin 2/2 100% • 2013: TropNet "GiardiaREF" study kick-off: Study on efficacy and tolerability of two 2nd-line regimens in nitroimidazole-refractory giardiasis: Quinacrine JC 01.03.21 Meltzer E et al.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation

    Pharmacy Reengineering (PRE) V.0.5 Pre-Release Implementation

    PHARMACY REENGINEERING (PRE) Version 0.5 Pre-Release Implementation Guide PSS*1*129 & PSS*1*147 February 2010 Department of Veterans Affairs Office of Enterprise Development Revision History Date Revised Patch Description Pages Number 02/2010 All PSS*1*147 Added Revision History page. Updated patch references to include PSS*1*147. Described files, fields, options and routines added/modified as part of this patch. Added Chapter 5, Additive Frequency for IV Additives, to describe the steps needed to ensure correct data is in the new IV Additive REDACTED 01/2009 All PSS*1*129 Original version REDACTED February 2010 Pharmacy Reengineering (PRE) V. 0.5 Pre-Release i Implementation Guide PSS*1*129 & PSS*1*147 Revision History (This page included for two-sided copying.) ii Pharmacy Reengineering (PRE) V. 0.5 Pre-Release February 2010 Implementation Guide PSS*1*129 & PSS*1*147 Table of Contents Introduction ................................................................................................................................. 1 Purpose ....................................................................................................................................1 Project Description ....................................................................................................................1 Scope ........................................................................................................................................3 Menu Changes ..........................................................................................................................4
  • Abiraterone Acetate for Chemotherapy-Naive

    Abiraterone Acetate for Chemotherapy-Naive

    Fan et al. BMC Urology (2018) 18:110 https://doi.org/10.1186/s12894-018-0416-6 RESEARCHARTICLE Open Access Abiraterone acetate for chemotherapy- naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors Liancheng Fan†, Baijun Dong†, Chenfei Chi†, Yanqing Wang†, Yiming Gong†, Jianjun Sha, Jiahua Pan, Xun Shangguan, Yiran Huang, Lixin Zhou* and Wei Xue* Abstract Background: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. Methods: We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who were treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostate- specific antigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS), and overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied. Results: The median follow-up time was 14.0 months (range 7.0–18.5 months), at which time 19 death events had been reported: 11 in the AA + prednisone group and 8 in the prednisone group. The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23. 3 vs 17.5 months, P = 0.016) than the prednisone-alone group. The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11.6%) and 2 of 17 patients (11.8%), respectively.
  • Chemical Compounds As Carcinogenic Agents Second Supplementary Report: Literature of 1938 and 1939 Biological Considerations

    Chemical Compounds As Carcinogenic Agents Second Supplementary Report: Literature of 1938 and 1939 Biological Considerations

    CHEMICAL COMPOUNDS AS CARCINOGENIC AGENTS SECONDSUPPLEMENTARY REPORT: LITERATURE OF 1938 AND 1939 J. W. COOK AND E. L. KENNAWAY (From the Royal Cancer Hospital (Free), London, and the University of Glasgow) BIOLOGICALCONSIDERATIONS (Continued from page 428, Jitly 1940) II. Action of Carcinogenic Compounds in Difierent Species and Tissues A number of reports of the action of carcinogenic compounds on human tis- sues have appeared. Klar (601) developed a nodule on the forearm after completion of a series of experiments with 3:4-benzpyrene. He applied a solution of the hydrocarbon (0.25 per cent in benzol) to the skin of mice with a paint brush and for at least part of the period wore rubber gloves. He also conducted experiments, of which no description is given, with the powdered hydrocarbon contained in a glass vessel. Three months after the completion of the experiments a small nodule appeared on the dorsum of the left forearm, This was excised in May 1938 and described by Professor Huckel as a “ so- called benign calcifying epithelioma.” The growth extended into the subcu- taneous fatty tissue; the connection with the superficial epithelium is not described nor is it evident in the two photomicrographs which illustrate the report. The author does not state his age. Gordonoff and Walthard (562) record the occurrence of a tumor in a labo- ratory assistant, aged forty-two, engaged in applying methylcholanthrene (0.3 per cent in benzol) to the skin of mice. The site was in the nasolabial fold, at a spot often touched by the patient when smoking. The microscopic ap- pearance was that of a “ still well delimited stage of an incipient squamous- cell sarcoma.” Cottini and Mazzone (479) deliberately applied 3 :4-benzpyrene ( 1 per cent in benzene) to the skin, generally of the arm or thigh, of 26 patients with various cutaneous diseases, usually daily for periods up to 120 days.
  • Jos Journal 2

    Jos Journal 2

    POST-OPERATIVE AUDIT OF G6PD-DEFICIENT MALE CHILDREN WITH OBSTRUCTIVE ADENOTONSILLAR ENLARGEMENT AT UNIVERSITY COLLEGE HOSPITAL, IBADAN, NIGERIA. John EN1, Totyen EL1, Jacob N2, Nwaorgu OGB1 1 .Department of ENT/Head and Neck Surgery, University College Hospital, Ibadan, Nigeria 2. Department of paediatrics, University College Hospital, Ibadan, Nigeria All correspondences and request for reprint to Dr John EN, Department of ENT/Head and Neck Surgery, University College Hospital, Ibadan, Nigeria Email: [email protected] Telephone: +2348036240109 Abstract Background: G6PD deficiency ranks among the commonest hereditary enzyme deficiency worldwide and notable as a predisposing condition to haemolyticcrises. The fear of possible untoward effects is often expressed by parents of G6PD deficient male children scheduled for surgery after obtaining an informed and understood consent. The parental perception of obstructive adenotonsillar enlargement in this condition was also appraised. Methods: A retrospective chart review of all G6PD deficient male children between ages 1 to 7years who had adenotonsillectomy over a 3year period at University college Hospital, Ibadan, Nigeria. Results: The patients comprised of 22 G6PD deficient male children diagnosed shortly after birth upon development of neonatal jaundice. Fifteen(68.2%) and 6(27.3%) of the patients subsequently developed episodes of drug- induced haemolysis and non-haemolytic drug reactions prior to undergoing adenotonsillectomy by the otolaryngologists. None of the patients was observed to develop haemolytic crises up to 2weeks post-adenotonsillectomy. From the parental perception and responses in the follow-up period,all 22(100%) patient had resolution of noisy breathing, 20(91%) had improvement of snoring and apnoeic spells. Only 15 (68%) were reported to stop mouth-breathing.